Navigation Links
PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
Date:6/17/2008

BOSTON, June 17 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it is expanding its clinical pharmacology capabilities in the Central Nervous System (CNS) therapeutic area. PAREXEL is enhancing existing services in early phase clinical development by adding pain modeling capabilities and combining traditional pharmacodynamic methods with relevant biomarkers, which are surrogate endpoints used to determine safety and efficacy signals.

"CNS diseases, which are reported to account for one third of the world's disease burden, include neurodegenerative diseases such as Alzheimer's and conditions characterized by chronic pain," said Michelle Middle, MB, ChB, Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "Our global team of clinical pharmacology experts with in-depth CNS expertise applies various methodologies and biomarkers to help clients make earlier and more effective decisions regarding CNS treatments, and advance this important and growing area of research."

PAREXEL's dedicated clinical pharmacology services directed at alleviation of pain and related symptoms use neuroscience biomarkers to enhance exploration of safety and efficacy and pharmacokinetic analysis. This expanded approach for a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies provides greater information about CNS treatments in early phase development. This expertise is aided by the ability to conduct studies with healthy volunteer and patient populations in a time-efficient manner.

PAREXEL, which is a top provider of expertise-based early phase development services from
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
2. PAREXEL Reaches Agreement To Acquire ClinPhone
3. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
4. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
5. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
6. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
8. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
9. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., SINGAPORE, Dec. 2 S*BIO Pte L... oral JAK2 inhibitor, SB1518, at The American Soci...on in New Orleans. ,, Data will be presented on...tion trial of SB1518 detailing its safety, tolerab...profile in dose levels ranging from 100 to 600 mg....
(Date:12/2/2009)..., NANJING, China, Dec. 2 /PRNewswire-Asia/ -- ...mpany") (NYSE: SCR ), a leading pharmaceutical c...ing, and marketing of branded,generic and propriet... 105 of,its drugs have been included in China,s Na... issued by China,s Ministry of Human Resources and...
(Date:12/2/2009)..., SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The wo...are in turmoil and uncertainty is part of many,bus...ma industry has been,relatively immune to the econ...tion. , During the midst of the difficult... & Johnson inaugurated an R&D center in Sh...
(Date:12/2/2009)...HOBOKEN, N.J., Dec. 2 According to...5 percent of Americans diagnosed with diabetes alr...betic retinopathy, damage to the retina caused by ... in people with diabetes and is one of the most fe...rcent of all patients who,ve had diabetes for 10 y...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...fications, thereby providing scientists with a too...duction to drug discovery. However, this sophistic...ing the threat of engineered pathogens. New resear...ome Biology shows that computational tools could b...ally engineered bacteria in environmental samples....
...ISE, Fla., March 17 Bioheart, Inc.,(Nasdaq: BHRT...elop,autologous (patient-derived) cell therapies a...heart damage, today announced that company founder...transition from Executive,Chairman and become Chai...,serves as the company,s Chief Technology Officer ...
...rch 19 at 10:00 AM EDT, CEDAR KNOLLS, N.J., March... today announced its financial results for,the fou...isphere will host a conference call to discuss fou...ch 19, 2008. A live webcast of the conference,call...: http://www.emisphere.com .,The live conference ...
Other Biology Technology:On the trail of rogue genetically modified pathogens 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 3Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 2Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 3Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 5Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 6Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 7Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 8
(Date:12/2/2009)..., , REDWOOD CITY, Calif., Dec. 2 /PRNews...rint identity and authentication solutions, today ...del of its DigitalPersona biometric fingerprint te...gitalPersona U.are.U® 4500HD offering allows ...kly identify users so that specific transactions c...
(Date:12/2/2009)..., , Before one of your muscles can twitch, before... nerve, a tiny floodgate of sortscalled an ion cha... organs to let in the chemical signals that spur t...nstitute of Standards and Technology (NIST) has al...e surface membrane for the first time, potentially...
(Date:12/2/2009)..., New York, NY, December 2, 2009 Commonly prescr...ment of asthma in pregnant women as well as pre-te...trum disorders, psychiatric pathology, cognitive p...ren, according to a new study published in the Dec...trics & Gynecology . , Beta 2 adrenergic agonist...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Nervy research: Researchers take initial look at ion channels in a model system 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2IH Systems RIVA Top Pick for Directors of Pharmacy 57370 1IH Systems RIVA Top Pick for Directors of Pharmacy 57370 2HMS Awarded Third Party Liability Services Contract by Minnesota 57366 1Dr Drew and Drug Czar Host Online Chat 57362 1
...009) The Michael & Susan Dell Center for Advancem...chool of Public Health Austin Regional Campus will...eship in Child Health at 1:30 p.m. Thursday, April...e Center Amphitheater in Austin. , Obesity expe...biostatistics and epidemiology at the University o...
...astatic prostate cancer has shown considerable pro...hose disease has become resistant to current drugs...gues at several other institutions, including Memo... new drug to treat a particularly lethal form of t... cancer, or CRPC. Also referred to as hormone-refr...
...9, 2009 -- Four experts in soil carbon research, f...tunity farmers and foresters have to manage soil c...ate in voluntary markets. Agricultural and forest ...50 million metric tons of carbon dioxide (CO 2 ) e... gas emissions. , The briefing, "Down to Earth Ca...
Other Biology News:Annual Michael & Susan Dell lectureship in child health 2New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Down to Earth carbon science: Briefing April 15 in DC 2
Mouse Anti-PDK1 Docking Motif, phospho (Ser / Thr) Monoclonal Antibody, Unconjugated, Clone 18A2 from Cell Signaling Technology
Mouse Anti-Human Clusterin alpha chain Monoclonal Antibody, Unconjugated, Clone 41D from Upstate
Rabbit Anti-Human MT3-MMP Membrane-Type Metalloproteinase-3, propeptide domain, Antibody, Unconjugated from CEDARLANE Laboratories Limited
Rabbit Anti-Methionine Aminopeptidase 2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: